High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer ; volume:13 ; number:1 ; day:7 ; month:9 ; year:2022 ; pages:1-20 ; date:12.2022
Nature Communications ; 13, Heft 1 (7.9.2022), 1-20, 12.2022
- Creator
-
Palafox, Marta
Monserrat, Laia
Bellet, Meritxell
Villacampa, Guillermo
Gonzalez-Perez, Abel
Oliveira, Mafalda
Brasó-Maristany, Fara
Ibrahimi, Nusaibah
Kannan, Srinivasaraghavan
Mina, Leonardo
Herrera-Abreu, Maria Teresa
Òdena, Andreu
Sánchez-Guixé, Mònica
Capelán, Marta
Azaro, Analía
Bruna, Alejandra
Rodríguez, Olga
Guzmán, Marta
Grueso, Judit
Viaplana, Cristina
Hernández, Javier
Su, Faye
Lin, Kui
Clarke, Robert B.
Caldas, Carlos
Arribas, Joaquín
Michiels, Stefan
García-Sanz, Alicia
Turner, Nicholas C.
Prat, Aleix
Nuciforo, Paolo
Dienstmann, Rodrigo
Verma, Chandra S.
Lopez-Bigas, Nuria
Scaltriti, Maurizio
Arnedos, Monica
Saura, Cristina
Serra, Violeta
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-32828-6
- URN
-
urn:nbn:de:101:1-2023012809095236892936
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Palafox, Marta
- Monserrat, Laia
- Bellet, Meritxell
- Villacampa, Guillermo
- Gonzalez-Perez, Abel
- Oliveira, Mafalda
- Brasó-Maristany, Fara
- Ibrahimi, Nusaibah
- Kannan, Srinivasaraghavan
- Mina, Leonardo
- Herrera-Abreu, Maria Teresa
- Òdena, Andreu
- Sánchez-Guixé, Mònica
- Capelán, Marta
- Azaro, Analía
- Bruna, Alejandra
- Rodríguez, Olga
- Guzmán, Marta
- Grueso, Judit
- Viaplana, Cristina
- Hernández, Javier
- Su, Faye
- Lin, Kui
- Clarke, Robert B.
- Caldas, Carlos
- Arribas, Joaquín
- Michiels, Stefan
- García-Sanz, Alicia
- Turner, Nicholas C.
- Prat, Aleix
- Nuciforo, Paolo
- Dienstmann, Rodrigo
- Verma, Chandra S.
- Lopez-Bigas, Nuria
- Scaltriti, Maurizio
- Arnedos, Monica
- Saura, Cristina
- Serra, Violeta
- SpringerLink (Online service)
Other Objects (12)
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Regulation of CDK4
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Loss of CDK4/6 activity in S/G2 phase leads to cell cycle reversal
Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents
Novel compound heterozygous MYO15A splicing variants in autosomal recessive non-syndromic hearing loss
ANK3 related neurodevelopmental disorders: expanding the spectrum of heterozygous loss-of-function variants
Compound heterozygous PLA2G6 loss-of-function variants in Swaledale sheep with neuroaxonal dystrophy
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Regulation of CDK4
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Loss of CDK4/6 activity in S/G2 phase leads to cell cycle reversal
Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents
Novel compound heterozygous MYO15A splicing variants in autosomal recessive non-syndromic hearing loss
ANK3 related neurodevelopmental disorders: expanding the spectrum of heterozygous loss-of-function variants
Compound heterozygous PLA2G6 loss-of-function variants in Swaledale sheep with neuroaxonal dystrophy
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Regulation of CDK4
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Loss of CDK4/6 activity in S/G2 phase leads to cell cycle reversal
Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly
Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents
Novel compound heterozygous MYO15A splicing variants in autosomal recessive non-syndromic hearing loss
ANK3 related neurodevelopmental disorders: expanding the spectrum of heterozygous loss-of-function variants